Geoffrey Oxnard, MD
We are making tremendous headway in the development of potent yet tolerable targeted therapies for advanced lung cancers. To offer our patients the best care, we need to be familiar with the growing range of therapies which are emerging onto the market.
Needham, MA (PRWEB) November 02, 2016
Lung cancer claims more lives in the U.S. than breast, prostate and colon cancer combined. To help raise awareness, November has been designated Lung Cancer Awareness Month, and OMedLive is joining the cause with three complementary continuing medical education programs for clinicians treating advanced lung cancers.
The statistics are tough. According to the American Lung Association, 158,080 people will likely die from lung cancer in 2016, many less than a year after receiving the harrowing news. For clinicians, the often short window of treatment time means that their own expertise marks a watershed in the life of each lung cancer patient. Thankfully, many recent medical advances are providing hope.
“We are making tremendous headway in the development of potent yet tolerable targeted therapies for advanced lung cancers,” says Geoffrey R. Oxnard, M.D., thoracic oncologist at Dana-Farber Cancer Institute and Assistant Professor at Harvard Medical School.
“To offer our patients the best care, we need to be familiar with the growing range of therapies which are emerging onto the market.”
Recent insight into molecular and genetic profiling of non-small cell lung cancer (NSCLC) tumors, which constitute up to 90% of lung cancers, as well as emerging immunotherapies have expanded and personalized treatment options.
To help spread the knowledge, OMedLive is offering the following three complimentary CME programs for medical oncologists, oncology nurses, nurse practitioners, physician assistants, primary care physicians, pulmonologists, and others interested in the therapeutic management of patients with lung cancer.
Immunotherapy: Shifting the Lung Cancer Treatment Paradigm: November 3rd, 2:00 – 3:00PM EST
Learn More and Register Here
Updates in the Lung Cancer: Targeting the Epidermal Growth Factor Receptor
Learn More and Register Here
Updates in Lung Cancer: ALK Inhibition in the Treatment of NSCLC
Learn More and Register Here
About OMedLive
OMedLive is an online CME learning platform from PlatformQ Health that offers advanced, accredited and complementary medical education to clinicians in a highly accessible and convenient format. OMedLive’s programs are available live and on demand, and include all of the features of an in-person medical conference such as lectures, panel discussions and case presentations as well as interactive polling and Q&A sessions with top faculty.